NCT00912054终止3 期
DuoTrav APS Versus XALACOM® in Ocular Surface Health
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 终止
- 入组人数
- 240
- 试验地点
- 1
- 主要终点
- Mean change from baseline (Day 0) in Ocular Surface Disease at the end of the treatment period (Day 90)
研究概览
简要总结
To demonstrate superiority of DuoTrav APS over XALACOM® in Ocular Surface Health in patients with open angle glaucoma or ocular hypertension.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients ≥ 18 years of age.
- •Must have a clinical diagnosis of open-angle glaucoma (with or without pseudoexfoliation or pigment dispersion component), or ocular hypertension in at least one eye.
- •Must be willing and able to discontinue use of any topical ocular medication other than the study medication for the duration of the study.
- •Must have had IOP controlled with mono-therapy using XALACOM for at least 1 continuous month prior to Visit
- •Women of childbearing potential must meet all specific conditions at Visit 1:
排除标准
- •Any abnormality preventing reliable applanation tonometry in the study eye(s).
- •Presence of any ocular pathology in either eye seen during the slit lamp or fundus exams that may preclude the safe administration of test article or safe participation in this study.
- •Dry eye or KCS which has been, or is currently being, treated with the use of punctal plugs, punctal cautery, Restasis®, or topical ocular corticosteroids.
- •Patients who have undergone keratorefractive ocular laser procedures, corneal surgery or surgery to the corneal surface, within 1 year prior to Visit1
- •Any other ocular laser surgery in either eye within 3 months
- •Patients who have undergone intraocular or extra-ocular surgery, in either eye, within 6 months prior to Visit
- •History of other progressive retinal or optic nerve disease.
- •Severe central visual field loss in either eye based upon the clinical judgment of the investigator.
- •Any history of, or current evidence of, infectious or inflammatory ocular conditions
- •Ocular trauma within 6 months prior to Visit 1 in either eye, as determined by patient history and/or examination.
- •History or evidence of corneal transplant or transplant variant procedures
- •Patients with suspected or diagnosed Sjogren's syndrome.
- •History of or current bronchial asthma, or severe chronic obstructive pulmonary disease
- •History of or current severe, unstable or uncontrolled cardiovascular, hepatic, or renal disease.
- •History of spontaneous or current hypoglycemia or uncontrolled diabetes.
- •History of or current severe allergic rhinitis and bronchial hyper reactivity.
- •Intolerance/hypersensitivity to any component of the medication
- •Use of any systemic medications on a chronic basis that have not been on a stable dosing regimen for at least 30 days prior to Visit 1, or an anticipated change in dosing regimen of medications during the course of the study.
- •Use of ocular medications other than XALACOM® within 7 days
- •Use of corticosteroids within 30 days of Visit 1, or any anticipated use of corticosteroids during the course of the study.
- •Use of contact lenses within 30 days of Visit
- •Concomitant use of contact lenses is also excluded for the duration of the study.
研究组 & 干预措施
1
Experimental
DuoTrav APS
干预措施: DuoTrav APS (Drug)
2
Active Comparator
Xalacom
干预措施: Xalacom (Drug)
结局指标
主要结局
Mean change from baseline (Day 0) in Ocular Surface Disease at the end of the treatment period (Day 90)
时间窗: Visits 1 and 3
次要结局
- Percent of patients with a corneal fluorescein staining score of 0 at the end of the treatment period (Day 90)(Visit 3 (Day 90))
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Travoprost APS Versus Xalatan® in Patient Reported Outcomes and Ocular Surface HealthOpen Angle GlaucomaOcular HypertensionNCT00892762Alcon Research434
已完成
4 期
Comparison of Efficacy and Ocular Surface Disease Assessment Between Monoprost and BAK-preserved LatanoprostGlaucomaOcular HypertensionNCT04743622CHA University57
已完成
4 期
Cosopt Versus XalacomOpen-Angle GlaucomaOcular HypertensionNCT00273481Pharmaceutical Research Network33
已完成
不适用
Evaluation of the VisuXL® Performance on Ocular Surface DiscomfortOcular DiscomfortNCT03844737VISUfarma SpA20
已完成
3 期
Comparison Study of ISV-303 to Durasite Vehicle in Cataract Surgery SubjectsOcular InflammationNCT01808547Sun Pharmaceutical Industries Limited268